VIDENCE AND VALUES: REQUIREMENTS FOR PUBLIC REIMBURSEMENT OF DRUGS FOR RARE DISEASES - A CASE STUDY IN ONCOLOGY
Main Article Content
Keywords
Cost-effectiveness, ethics, health policy, clinical trials
Abstract
Introduction
Doubts have been expressed about whether standard methods of health technology assessment are suitable for the evaluation of drugs for rare diseases. Under conditions of rarity, it may be more difficult to conduct large randomized trials in order to gather adequate evidence on efficacy, and the standard methods of economic evaluation may not adequately reflect societal preferences for the treatment of serious and/or life-threatening rare diseases.
Methods
A roundtable was held at the University of Toronto Joint Centre for Bioethics on February 18, 2008 to address these issues. While the focus was on evaluation and reimbursement decision-making for rare cancers, the discussion was broadened to consider the place of evidence and values in considering public reimbursement of drugs prescribed for rare disorders more generally.
Discussion
This paper explores the relevant issues in more detail, using the example of a new drug for treatment of renal cell carcinoma.
Conclusion
There should be a greater commitment by reimbursement agencies to a fair and transparent decisionmaking process with appropriate community input. Criteria should be developed to validate surrogate markers for rare diseases. It should also be acknowledged that the traditional measures of benefit in economic studies do not incorporate all elements of social value. The need should be recognized to balance equity with an efficient use of resources.
References
2. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1993.
3. Canadian Agency for Drugs and Technologies in Health (CADTH). Common drug review. http://www.cadth.ca/media/pdf/186_EconomicG uidelines_e.pdf. (Accessed on: September 2, 2008).
4. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007; 23(1): 36-42.
5. Laupacis A. Economic evaluations in the Canadian Common Drug Review. Pharmacoecon 2006;24(11):1157-62.
6. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf Kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). 41st American Society of Clinical Oncology (ASCO) Annual Meeting 2005 May 15-17, Orlando, FL. J Clin Oncol 2005; Abst 4510.
7. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1401-11.
8. Escudier B, Szczylik C, Eisen T, et al. Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC), 13th European Conference on Clinical Oncology (ECCO), November 3, 2005; Paris, France. Abst 794.
9. Eisen T, Bukowski RM, Staehler M, et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival, 42nd American Society of Clinical Oncology (ASCO) Annual Meeting. June 2-6, 2006, Atlanta GA. J Clin Oncol 2006;24(Jun 20 Suppl); Abst 4524.
10. George B, Harris A, Mitchell A. Costeffectiveness analysis and the consistency of decision-making: Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001;19:1103-9.
11. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7.
12. Martin DK, Pater JL, Singer PA. Priority-setting decisions for new cancer drugs: A qualitative study. Lancet 2001;358:1676-81.
13. Culyer AJ. Equity of what in health care? Why the traditional answers don’t help policy - and what to do in the future. Healthcare Papers 2007; 8(Suppl):12-26.
14. Daniels N, Sabin JE. Setting limits fairly: Can we learn to share medical resources? New York: Oxford University Press, 2002.
15. Martin D, Singer P. A strategy for improved priority setting in health care institutions. Health Care Anal 2003;11:59-68.
16. Trotta F, Apolone G, Garattini S, Tafuri G. Stopping a trial early in oncology: for patients or for industry? Ann Oncol 2008;19:1347-53.
17. Lassere MN, Johnson KR, Boers M, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 2007;34:607-15.
18. Lassere MN, Johnson KR, Hughes M, et al. Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches. J Rheumatol 2007;34:616- 9.
19. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT Filter for outcome measures in rheumatology. J Rheumatol 1998;25:198-9.
20. Guyatt GH, Oxman AD, Vist GE, et al, for the GRADE working group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
21. Clarke JTR. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. Can Med Assoc J 2006;174:189-90.
22. Coyle D, Tosteson ANA. Towards a reference case of future economic evaluations of interventions in osteoarthritis. J Rheumatol 2003;30(Suppl 68):31-36.
23. Drummond MF, Maetzel A, Gabriel S, March L. Towards a reference case for use in future economic evaluations of interventions in osteoarthritis. J Rheumatol 2003;30(Suppl 68):26-30.
24. Maetzel A, Tugwell P, Boers M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891-6.
25. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoecon 2006;24:1055-68.
26. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare’s ‘Coverage with evidence development’. Health Affairs 2006;25:1218-30.
27. Report of the Standing Committee on Health. Prescription drugs. Part 1 – Common Drug Review: An F/P/T Process. House of Commons, Canada, 39th Parliament, 2nd session, Ottawa, December 2007. http://cmte.parl.gc.ca/Content/HOC/committee/3 92/hesa/reports/rp3162492/hesarp02/hesarp02- e.pdf ( Accessed on: September 2, 2008).
28. Levin L, Goeree R, Sikich N, et al. Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: The Ontario experience. Int J Technol Assess Health Care 2007;23(3):299- 309.